HCM - HUTCHMED (China) Limited
NASDAQ
->
Healthcare
->
Biotechnology
Central,
Hong Kong
Type: Equity
HCM price evolution
HCM
| (in millions $) | 30 Jul 2024 | 31 Jan 2024 | 30 Jul 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $106 | $71.24 | $178.33 | |
| Short term investments | ||||
| Net receivables | $192.28 | $167.18 | $128.66 | |
| Inventory | $46.44 | $53.88 | $56.69 | |
| Total current assets | $1048.26 | $1090.48 | $839.89 | |
| Long term investments | ||||
| Property, plant & equipment | $94.81 | $96.83 | $84.67 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $1260.87 | $1297.5 | $1029.44 | |
| Current liabilities | ||||
| Accounts payable | $43.4 | $54.58 | $71.11 | |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $373.29 | $340.86 | $353.9 | |
| Long term debt | $55.63 | $40.15 | $23.3 | |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $520.78 | $515.46 | $419.08 | |
| Shareholders' equity | ||||
| Retained earnings | -$845.07 | -$803.06 | -$971.48 | |
| Other shareholder equity | -$9.53 | -$7.8 | -$1.9 | |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $178.33 | $377.54 | $235.63 | |
| Short term investments | $636.92 | $202.93 | ||
| Net receivables | $128.66 | $147.73 | $64.44 | |
| Inventory | $56.69 | $35.76 | $19.77 | |
| Total current assets | $839.89 | $1212.08 | $530.74 | |
| Long term investments | $76.48 | $139.5 | ||
| Property, plant & equipment | $84.67 | $53.15 | $32.19 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $193.38 | |||
| Total investments | ||||
| Total assets | $1029.44 | $1372.66 | $724.12 | |
| Current liabilities | ||||
| Accounts payable | $71.11 | $41.18 | $31.61 | |
| Deferred revenue | $1.6 | |||
| Short long term debt | $26.91 | |||
| Total current liabilities | $353.9 | $311.66 | $158.4 | |
| Long term debt | $23.3 | $7.16 | $27.44 | |
| Total noncurrent liabilities | $46.77 | |||
| Total debt | $36.69 | |||
| Total liabilities | $419.08 | $333.15 | $205.17 | |
| Shareholders' equity | ||||
| Retained earnings | -$971.48 | -$610.33 | -$415.59 | |
| Other shareholder equity | -$1.9 | $5.57 | $4.48 | |
| Total shareholder equity | $986.89 | $484.12 | ||
| (in millions $) | 30 Jul 2024 | 31 Jan 2024 | 30 Jul 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $305.68 | $305.13 | $532.87 | $224.36 |
| Cost of revenue | ||||
| Gross Profit | $125.55 | $129 | $324.55 | $50.58 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $153.07 | $222.28 | $212.9 | $261.52 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $2.89 | $1.78 | $2.73 | $3.93 |
| Interest expense | $33.81 | $12.19 | $35.11 | $16.2 |
| Net income | ||||
| Net income | $25.8 | -$67.77 | $168.55 | -$197.97 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $838 | $426.41 | $356.13 | $227.98 |
| Cost of revenue | $557.32 | $363.3 | ||
| Gross Profit | $453.55 | $115.31 | -$201.19 | -$135.32 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $127.13 | $61.35 | ||
| Total operating expenses | $435.18 | $523 | $684.45 | $424.64 |
| Operating income | -$328.32 | -$196.67 | ||
| Income from continuing operations | ||||
| EBIT | -$328.32 | -$196.67 | ||
| Income tax expense | $4.51 | -$0.28 | $11.92 | $4.83 |
| Interest expense | $91.34 | $58.7 | -$0.59 | -$0.79 |
| Net income | ||||
| Net income | $100.78 | -$360.83 | -$194.65 | -$125.73 |
| Income (for common shares) | -$194.65 | -$125.73 | ||
| (in millions $) | 30 Jul 2024 | 31 Jan 2024 | 30 Jul 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$5.43 | -$291.14 | -$315.96 | $296.59 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$32.56 | $48.66 | $5.83 | -$82.76 |
| Effect of exchange rate | -$1.81 | -$6.47 | -$6.56 | -$9.49 |
| Change in cash and equivalents | -$79.64 | -$29.69 | -$90.28 | -$64.26 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | -$194.65 | -$125.73 | ||
| Operating activities | ||||
| Depreciation | $7.19 | $6.06 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$204.22 | -$62.07 | ||
| Investing activities | ||||
| Capital expenditures | -$16.4 | -$7.95 | ||
| Investments | -$275.49 | -$103.53 | ||
| Total cash flows from investing | -$291.14 | $296.59 | -$306.32 | -$125.44 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$0.58 | |||
| Total cash flows from financing | $48.66 | -$82.76 | $650.03 | $296.43 |
| Effect of exchange rate | -$6.47 | -$9.49 | $2.43 | $5.55 |
| Change in cash and equivalents | -$29.69 | -$64.26 | $141.91 | $114.47 |
News
Fundamentals
| Market cap | $2.31B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 170.52M |
| Revenue | $1.37B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$71.39M |
| Revenue Q/Q | 51.29% |
| Revenue Y/Y | N/A |
| P/E ratio | -32.36 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 1.69 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.62 |
| EPS | -$0.42 |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.81 |
| Quick ratio | 2.68 |